6,404 Shares in Tempus AI, Inc. (NASDAQ:TEM) Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 6,404 shares of the company’s stock, valued at approximately $216,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Horizon Advisors Inc. bought a new stake in Tempus AI in the third quarter valued at approximately $30,000. FNY Investment Advisers LLC bought a new stake in Tempus AI in the fourth quarter valued at approximately $67,000. IFP Advisors Inc bought a new stake in Tempus AI in the fourth quarter valued at approximately $76,000. US Bancorp DE bought a new stake in Tempus AI in the fourth quarter valued at approximately $80,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Tempus AI in the fourth quarter valued at approximately $178,000. Institutional investors own 24.22% of the company’s stock.

Insiders Place Their Bets

In other news, Director David R. Epstein sold 990 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $46.83, for a total value of $46,361.70. Following the completion of the transaction, the director now directly owns 26,284 shares in the company, valued at approximately $1,230,879.72. This represents a 3.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now owns 57,237 shares of the company’s stock, valued at $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,598,969 shares of company stock worth $317,194,162 over the last three months.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on TEM shares. JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and upped their target price for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. William Blair reissued a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Loop Capital reduced their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Finally, TD Cowen reissued a “buy” rating and set a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $61.18.

Tempus AI Price Performance

NASDAQ TEM opened at $51.35 on Monday. The business has a fifty day moving average price of $56.35 and a two-hundred day moving average price of $51.38. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.